Clinical Trial Update: Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Ecraprost in lipid emulsion for critical leg ischemia due to peripheral arterial disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Artery Disease
• Peripheral Vascular Disease

Drugs mentioned

• Ecraprost

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Peripheral Vascular Disease | Phase 3 | Status: COMPLETED